August 6, 2024
Santen and Cloudbreak enter licence agreement for pterygium treatment
Santen Pharmaceutical has entered into a licensing agreement with Cloudbreak Pharma to develop, manufacture, and commercialise CBT-001, a topical pterygium treatment, for certain territories.